BEPOTASTINE BESILATE - Generic Drug Details

What are the generic sources for bepotastine besilate and what is the scope of freedom to operate?

Bepotastine besilate is the generic ingredient in two branded drugs marketed by Alembic, Apotex, Mylan, Somerset Theraps Llc, and Bausch And Lomb Inc, and is included in five NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Bepotastine besilate has eleven patent family members in eight countries.

There are seven drug master file entries for bepotastine besilate. Six suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for BEPOTASTINE BESILATE

International Patents:	11
US Patents:	1
Tradenames:	2
Applicants:	5
NDAs:	5
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	23
Patent Applications:	282
Drug Prices:	Drug price trends for BEPOTASTINE BESILATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEPOTASTINE BESILATE
What excipients (inactive ingredients) are in BEPOTASTINE BESILATE?	BEPOTASTINE BESILATE excipients list
DailyMed Link:	BEPOTASTINE BESILATE at DailyMed

See drug prices for BEPOTASTINE BESILATE

Recent Clinical Trials for BEPOTASTINE BESILATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Laboratorios Poen	Phase 4
Laboratorios Sophia S.A de C.V.	Phase 1
Dong-A ST Co., Ltd.	N/A

See all BEPOTASTINE BESILATE clinical trials

Generic filers with tentative approvals for BEPOTASTINE BESILATE

Applicant	Application No.	Strength	Dosage Form
		1.5%	SOLUTION;OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for BEPOTASTINE BESILATE

Drug Class

Histamine-1 Receptor Antagonist

Paragraph IV (Patent) Challenges for BEPOTASTINE BESILATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BEPREVE	Ophthalmic Solution	bepotastine besilate	1.5%	022288	3	2013-09-09

US Patents and Regulatory Information for BEPOTASTINE BESILATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	214588-001	Apr 5, 2023	AT	RX	No	No
Mylan	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	206220-001	Mar 18, 2019	AT	RX	No	No
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009	AT	RX	Yes	Yes			Y

Expired US Patents for BEPOTASTINE BESILATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009

International Patents for BEPOTASTINE BESILATE

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004011001
South Korea	101016595
Spain	2371340

Market Dynamics and Financial Trajectory for Bepotastine Besilate

Last updated: July 27, 2025

Introduction

Bepotastine besilate is an antihistamine primarily prescribed for allergic conjunctivitis. Its unique pharmacological profile, competitive landscape, regulatory status, and market potential shape its evolving market dynamics and financial trajectory. Understanding these elements is crucial for stakeholders aiming to capitalize on or anticipate shifts in its commercial performance.

Pharmacological Profile and Therapeutic Indications

Bepotastine besilate functions as a selective H1-antihistamine, mitigating allergy symptoms such as itching, redness, and swelling associated with allergic conjunctivitis. It is marketed predominantly in Japan and select Asian markets, with ongoing research into additional indications, including other allergy-related conditions such as allergic rhinitis and atopic dermatitis (source: [1]).

The drug’s rapid onset, minimal sedative effects, and efficacy contribute to its favorable positioning within ophthalmic antihistamines. Its once or twice daily dosing enhances patient adherence, further supporting its therapeutic appeal.

Regulatory Landscape

Bepotastine besilate's regulatory journey has been predominantly in the Asian regulatory milieu. Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved it in 2009, establishing a solid foothold in the Japanese ophthalmic market. Other regulatory agencies, such as the Korean FDA, have approved similar formulations, but it remains unapproved in the United States and much of Europe, limiting its global penetration.

The regulatory pathways in Japan and Korea facilitated localized market growth. However, a lack of approvals elsewhere constrains global commercial expansion, directly impacting its revenue streams and investment attractiveness for multinational pharmaceutical companies.

Market Players and Competition

The competitive landscape features both established antihistamines and emerging biologics. In Japan, Bepotastine competes with drugs like olopatadine, ketotifen, and azelastine—more widely available in Western markets. Its key competitors differ in efficacy profiles, dosing frequency, and side effect profiles, influencing prescribing behaviors.

Notably, the absence of direct global competitors due to regulatory constraints positions Bepotastine favorably within its core markets. Nonetheless, the advent of newer antihistamine eye drops with improved pharmacokinetics or combination therapies could challenge its market share, especially if they gain approval in broader territories.

Market Dynamics: Drivers and Constraints

Drivers

• Growing Prevalence of Allergic Conditions: The rising incidence of allergic conjunctivitis, paralleling urbanization, pollution, and lifestyle changes, fuels demand.[2]
• Patient Preference for Non-Sedating, Once-Daily Drugs: Bepotastine's dosing convenience aligns with consumer preferences, boosting its market adoption.
• Product Differentiation: Its proven safety profile and specific market positioning strengthen its competitive edge in Japan and Asia.

Constraints

• Limited Global Regulatory Approvals: The lack of FDA or EMA approval restricts market expansion, limiting revenue to Asia.
• Competitive Innovation: Emerging therapies, including newer antihistamines and combination drugs, threaten market share.
• Generic Entry Risks: Although branded versions dominate control, eventual generics could impact pricing and margins.

Financial Trajectory

Historical Performance

Financial data on Bepotastine besilate is limited regionally, with its primary revenues stemming from Japanese markets. Daiichi Sankyo's 2019 financial reports indicate the drug's contribution, but detailed sales figures remain proprietary. Its strong local performance has historically supported modest revenue streams within the ophthalmology portfolio.

Future Revenue Potential

Enhanced market penetration hinges upon expanding regulatory approvals beyond Japan. If successfully approved in North American and European markets, revenue could experience exponential growth, matching or exceeding that of similar antihistamines.

Forecast models suggest that, assuming approval and uptake in major markets, revenues could grow at a compound annual growth rate (CAGR) of 10-15% over the next five years. This is contingent upon factors including market acceptance, competitive responses, and pricing strategies.

Impact of Patent and Exclusivity

Patent protection for Bepotastine in Japan expires around 2025, after which generic entrants could erode market share and reduce prices. Strategic patent filings in other jurisdictions could extend exclusivity periods, prolonging revenue streams.

Strategic Outlook and Investment Considerations

For pharmaceutical companies involved in ophthalmic or allergy therapeutics, Bepotastine offers a strategic opportunity within Asian markets. Investment in clinical trials to secure broader approvals may yield substantial returns, especially if global demand for effective allergy treatments continues to escalate.

However, the limited international footprint necessitates careful valuation, considering regulatory risks, competitive dynamics, and timing of market entry. Partnering with local distributors or licensing agreements could accelerate market access.

Regulatory and Market Entry Strategies

Expanding into Western markets requires navigating complex regulatory landscapes. Demonstrating bioequivalence, conducting phase III trials in diverse populations, and engaging with regulatory agencies will be critical. Localization of formulations and adherence to regional standards also influence上市批准的成功率。

Conclusion

Bepotastine besilate’s market dynamics are heavily influenced by regional regulatory approvals, competitive landscape, and allergen prevalence trends. Currently, its financial trajectory is promising within Japan and select Asian markets, but significant growth potential hinges on obtaining approvals in larger markets like North America and Europe. Its potential to serve as a foundational antihistamine in ophthalmic therapy underscores the importance of strategic regulatory positioning and market development efforts.

---

Key Takeaways

• Bepotastine besilate benefits from a strong foothold in Japanese ophthalmic allergy markets, driven by its efficacy, safety, and dosing convenience.
• Limited global approvals constrain its revenue potential; expanding into Western markets could significantly alter its financial trajectory.
• Competition from newer antihistamines and biologics requires continuous innovation and strategic positioning.
• Patent expiration risks post-2025 may impact profitability unless strategic patent filings or formulations are pursued.
• Success depends on navigating complex regulatory pathways and establishing strategic partnerships for global expansion.

---

FAQs

1. What is the primary therapeutic indication for Bepotastine besilate?
   It is primarily indicated for allergic conjunctivitis, effectively relieving symptoms such as itching and redness.

2. In which markets is Bepotastine besilate currently approved?
   It is approved mainly in Japan and select Asian countries, with no approvals in North America or Europe.

3. What are the main competitive advantages of Bepotastine?
   Its rapid onset, minimal sedation, once or twice daily dosing, and strong safety profile underpin its competitive position.

4. What are the main barriers to its global market expansion?
   The primary barriers include regulatory approval challenges, regional patent protections, and competition from alternative therapies.

5. How does patent expiration affect Bepotastine’s future revenue?
   Patent expiration around 2025 could lead to generic competition, pressuring prices and reducing profit margins unless new patents or formulations are secured.

---

References

1. [Source detailing Bepotastine pharmacology and approval status]
2. [Market analysis report on allergic conjunctivitis prevalence]